1. Generics Bulletin
  2. >>Products

Teva Moves Forward With LAI Olanzapine Trials

Triggers Payment For Partner MedinCell, After Risperidone Knocked Back By US FDA

 
• By Dave Wallace

Teva is starting Phase III trials for a long-acting injectable formulation of olanzapine, partner MedinCell has revealed. The move comes after the pair were knocked back on their partnered risperidone product earlier this year by the US FDA, with a new expected launch date for that product now also disclosed by the French company.

Injectable syringe vial blue liquid
Teva and MedinCell are developing olanzapine and risperidone LAIs • Source: Shutterstock

Teva has moved ahead with the start of Phase III trials for the mdc-TJK long-acting injectable olanzapine candidate which it has co-developed with its partner, Montpellier-based MedinCell.

The move comes after the partners were knocked back by the US Food and Drug Administration earlier this year for another long-acting injectable, the

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Value Added Medicines

More from Products